MucoLife Therapeutics
MucoLife Therapeutics is dedicated to revolutionizing mucus management in pulmonary diseases such as COPD and cystic fibrosis. Their mission is to develop innovative, first-in-class therapies that dissolve mucus plugs, improve lung function, and enhance patients' quality of life. With a strong research background and strategic partnerships, MucoLife aims to bring groundbreaking treatments to market and transform respiratory healthcare.
Industries
Nr. of Employees
small (1-50)
MucoLife Therapeutics
Products
Lead inhaled mucolytic (oligomer‑based)
An inhaled therapeutic candidate composed of an amino‑acid‑based oligomer designed to dissolve pathological mucus plugs in the airways by removing calcium ions, intended to restore airflow and reduce infection/inflammation in muco‑obstructive lung diseases.
Lead inhaled mucolytic (oligomer‑based)
An inhaled therapeutic candidate composed of an amino‑acid‑based oligomer designed to dissolve pathological mucus plugs in the airways by removing calcium ions, intended to restore airflow and reduce infection/inflammation in muco‑obstructive lung diseases.
Services
R&D activities to develop and test inhaled mucolytic candidates derived from mucin biology research, supporting progression toward first‑in‑human studies.
R&D activities to develop and test inhaled mucolytic candidates derived from mucin biology research, supporting progression toward first‑in‑human studies.
Expertise Areas
- Mucin biology and mucus pathophysiology
- Inhaled therapeutics development
- Mucolytic drug design
- Preclinical development and translational research
Key Technologies
- Amino‑acid oligomer therapeutics
- Calcium‑chelation mucolytic mechanism
- Inhalation drug delivery/formulation
- Preclinical mucus‑clearance assays
News & Updates
MucoLife Therapeutics announces a partnership with the US-based life science accelerator Health Wildcatters to accelerate the development of their COPD treatment, MLT-001.
Thaher Pelaseyed, CEO of MucoLife Therapeutics, will present their innovative COPD treatment, MLT-001, at the BioNTX iC³ Summit.
MucoLife Therapeutics officially launched with the goal to develop therapies that dissolve mucus obstructions in pulmonary diseases.
MucoLife Therapeutics announces a partnership with the US-based life science accelerator Health Wildcatters to accelerate the development of their COPD treatment, MLT-001.
Thaher Pelaseyed, CEO of MucoLife Therapeutics, will present their innovative COPD treatment, MLT-001, at the BioNTX iC³ Summit.
MucoLife Therapeutics officially launched with the goal to develop therapies that dissolve mucus obstructions in pulmonary diseases.